Form 4: Arcus Biosciences Director Kathryn Falberg Reports Stock and Option Grants

Director Kathryn Falberg reported the acquisition of restricted stock units and stock options in Arcus Biosciences.

Summary

• Kathryn E Falberg, a director of Arcus Biosciences, reported changes in beneficial ownership.
• On June 6, 2024, Falberg acquired 8,400 shares of common stock through restricted stock units (RSUs) and was granted options to purchase 24,000 shares of common stock.
• The RSUs vest fully on the earlier of June 6, 2025, or the next annual meeting of stockholders, and will fully vest upon a change in control of the company.
• The stock options, with an exercise price of $15.9, also vest fully on the earlier of June 6, 2025, or the next annual meeting of stockholders, and will fully vest and become exercisable upon a change in control.
• Following the reported transactions, Falberg directly owns 55,300 shares of common stock and indirectly owns 102,106 shares through a trust.
• Falberg also directly owns options to purchase 24,000 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports standard compensation practices. The vesting conditions are positive, but overall, it's a routine disclosure.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting conditions tied to the annual meeting and change in control provide incentives for long-term value creation and strategic alignment.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.

Stakeholder Impact

• The grant of equity to directors can align their interests with shareholders, potentially driving long-term value.

Key Dates